Compare Google Inc (GOOG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Natera Inc. Common Stock — how do they compare? Google Inc trades at $338.58 (market cap $4.30T), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Google Inc is far larger — about 75.4× Natera Inc. Common Stock's market cap, and Google Inc pays a 0.25% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 138 Days and Natera Inc. Common Stock for 0 Days on average.
| GOOG | NTRA | |
|---|---|---|
Market Cap | $4.30T | $57.03B |
Volume | 14,394,061 | 1,131,157 |
Sector | Media | Health |
52-Week High | $399.06 | $425.64 |
52-Week Low | $251.34 | $179.42 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $4.19T | $56.18B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $343.65, down 1.52% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $9.11 beating expectations by 218%, revenue growth accelerating to $402.84B in 2025, and net income margin expanding to 54.77%. Recent news highlights significant AI investments and legal challenges.
Alphabet presents a compelling investment case with strong earnings momentum and dominant market position, though investors face risks from aggressive capital expenditure, potential negative free cash flow, and ongoing securities litigation. The consensus price target of $435.24 suggests 27% upside potential from current levels.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
